Adamis Pharma jumps after FDA approves opioid overdose treatment

DMK Pharmaceuticals

18/10/2021 13:03

** Shares of drug developer  ADMP.O  soars 28.3% to $1.45
premarket
    ** Stock among top pct gainer across U.S. exchanges
    ** Co says U.S. FDA has approved ZIMHI - its naloxone
injection product candidate to treat opioid overdose (https://refini.tv/3n8iS0x)
    ** Naloxone blocks or reverses effects of the opioid,
including extreme drowsiness, slowed breathing and loss of
consciousness
    ** Co says commercial launch of ZIMHI is planned for Q1 of
2022
    ** Drug overdoses resulted in about 97,000 deaths in U.S.
during the 12-month period ending March 2021 - Centers for
Disease Control and Prevention
    ** Stock has more than doubled this year, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))